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Abstract 
Background: Microparticles (MPs) are small (<1 μm) cell membrane-derived vesicles that are formed in response 
to cellular activation or early stages of apoptosis. Increased plasma MP levels have been associated with liver disease 
severity. Here we investigated the clinical impact of ascites MPs in patients with decompensated liver cirrhosis.
Methods: Ascites and blood samples of 163 patients with cirrhosis (ascites n = 163, blood n = 31) were collected 
between February 2011 and December 2012. MPs were obtained from ascites and from blood by two-step ultracen-
trifugation and quantified by flow cytometry. Quantitative absolute MP levels were correlated with clinical and labora-
tory baseline parameters as well as patient outcomes. Ascites microparticles were stained with antibodies against 
CD66b (neutrophils) and CD3 (lymphocytes) in a subgroup of 60 matched patients.
Results: MPs were detected in all ascites and blood samples. Absolute ascites MP levels correlated with blood levels 
(r = 0.444, p = 0.011). Low ascites MP levels (<488.4 MP/μL) were associated with a poor 30-day survival probability 
(<488.4 MP/μL 71.1% vs. >488.4 MP/μL 94.7%, log rank p = 0.001) and such patients had a higher relative amount 
of ascites microparticles derived from neutrophils and lymphocytes. Low levels of ascites MPs, high MELD score and 
antibiotic treatment were independent risk factors for death within 30 days.
Conclusions: Ascites MP levels predict short-term survival along with the liver function in patients with decompen-
sated cirrhosis. Further studies which evaluate ascites MPs as disease specific biomarker with a validation cohort and 
which investigate its underlying mechanisms are needed. Neutrophils and lymphocytes contributed more frequently 
to the release of microparticles in patients with low ascites levels, possibly indicating an immune activation in this 
cohort.
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Background
Microparticles (MPs) are small membrane-derived 
extracellular vesicles (<1  μm) that are shed by all cell 
types after cellular activation and during early stages of 
apoptosis. As they are formed by outward blebbing of the 
cell membrane, MPs contain cellular proteins, RNA and 
miRNA [1–3]. MPs are important messengers in intercel-
lular communication and involved in various pathomech-
anistic processes. This explains why increasing plasma 
MP levels generally express disease activity and progres-
sion [4–9]. There are several diseases that are accompa-
nied by vascular damage and therefore trigger the release 
of specific MP subtypes. In diabetes mellitus circulating 
platelet-derived MPs correlate with the degree of vas-
cular damage, particularly if end-organ damage occurs 
[10]. MPs released by endothelial cells are involved in 
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coronary artery disease [11]. The fact that well estab-
lished therapies for coronary artery disease that improve 
patient outcomes, e.g. administration of statins, also 
reduce MP levels emphasizes the role of MPs as biomark-
ers of disease activity [12]. Importantly, MPs released in 
the context of inflammatory reactions or oxidative stress 
can be both the consequence as well as the active modu-
lator of pathological processes [13, 14].
In liver diseases, plasma MP subtypes correlate well 
with intrahepatic inflammation in chronic hepatitis C 
and steatohepatitis [15, 16] as well as severity of liver 
failure [17]. If chronic liver diseases are not adequately 
treated, they most often progress to cirrhosis with typical 
complications such as ascites. Because all cell types shed 
MPs, they can also be expected to occur in body fluids 
other than plasma. There are studies demonstrating MPs 
in synovial fluid [18], pleural fluid [19] and urine [20]. 
Another source of MP release is the peritoneum. Mrvar-
Brecko et  al. [21] used electron microscopy to visualize 
the presence of MPs in a patient with peritonitis and 
ascites. The largest cohort was investigated by Press et al. 
[22]. Using flow cytometry, they have nicely shown that 
tumor-derived MPs are detectable in all ascites samples 
of 41 patients with ovarian carcinoma and eight patients 
with benign ovarian neoplasms. However, evidence for 
the presence of MPs in ascites of patients with cirrhosis 
is missing.
We therefore investigated whether MPs are detectable 
in ascites of patients with decompensated cirrhosis and 
correlated the quantification level with patients’ clinical 
presentation and outcome.
Methods
Study design
In line with the institutional standards of the Section of 
Hepatology, University Hospital Leipzig, Germany, every 
patient presenting with ascites between February 2011 
and December 2012 was eligible for specimen banking 
and clinical data collection (n =  180). The study proto-
col conformed to the ethical guidelines of the 1975 Dec-
laration of Helsinki and was approved by the local ethics 
committee. All patients gave written informed consent.
All patients with ascites due to decompensated liver 
cirrhosis were eligible for inclusion in the present analy-
sis. Cirrhosis diagnosis was based on typical laboratory 
and morphological criteria. Exclusion criteria included 
immunosuppressive therapy, sepsis at baseline and 
malignant diseases other than hepatocellular carcinoma 
(HCC). Baseline was set at the first paracentesis of every 
patient after study inclusion. All further paracenteses 
were not considered for study analyses.
At baseline, the following parameters were assessed: 
etiology of cirrhosis, sex, age, body mass index (BMI), 
blood pressure, body temperature, drug history and 
clinical outcome, MELD (Model for End-Stage Liver Dis-
ease) score, liver and renal function tests [e.g. glomeru-
lar filtration rate (GFR)], international normalized ratio 
(INR), platelet count, white blood cell (WBC) count, 
serum sodium, transaminases [aspartate transaminase 
(AST), alanine transaminase (ALT)], gamma-glutamyl-
transferase (GGT), C-reactive protein (CrP), serum albu-
min and in ascites leukocyte count, protein and albumin 
content. Spontaneous bacterial peritonitis (SBP) was 
diagnosed according to Wong et al. [23] if the ascites leu-
kocyte count was elevated above 500/mm3. The ascites 
polymorphonuclear leukocyte (PMN) count, the gold 
standard for the diagnosis of SBP, was not available at this 
institution.
Patient characteristics
The study included 163 patients with liver cirrhosis, of 
which 21 (12.9%) were diagnosed with hepatocellular 
carcinoma. The main cause of cirrhosis was alcoholic 
liver disease (71.8%). All further baseline characteristics 
are displayed in Table 1.
Table 1 Baseline parameters at index paracentesis
Values are given in median (range) for continuous data and in absolute number 
(%) for discrete data
a MELD could not be calculated in 6/163 patients as at least one parameter was 
not available at paracentesis
b Child–Pugh score could not be calculated in 65/163 patients as at least one 
parameter was not available at paracentesis
Variable Value
Age (years) 59 (25–87)
Gender (male/female) n = 121/n = 42 (74.2%/25.8%)
Etiology
 Alcoholic n = 117 (71.8%)
 NASH n = 14 (8.6%)
 Viral n = 4 (2.5%)
 Others n = 28 (17.2%)
HCC n = 21 (12.9%)
Child–Pugh class (A/B/C)b n = 2/n = 60/n = 36 
(2%/61.2%/36.7%)
MELD  scorea 16.9 (7–38)
INR 1.4 (1–2.9)
Total bilirubin level (μmol/L) 39.5 (2.9–609.1)
Creatinine level (μmol/L) 108 (38–509)
WBC count (exp9/L) 6.6 (1.2–49.7)
AST (μkat/L) 0.87 (0.1–8.9)
GGT (μkat/L) 1.8 (0.2–22.4)
CrP (mg/L) 25.4 (1.2–186.2)
Serum albumin (g/L) 30.4 (16–47.3)
Ascites protein content (g/L) 11.6 (2.7–50.9)
Ascites leukocyte count (/mm3) 180 (0–12,300)
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Cirrhosis-associated complications were present at the 
time of index paracentesis with hepatic encephalopathy 
in 23 out of 163 patients (14.1%), hepatorenal syndrome 
in 41 out of 163 patients (25.2%) and hepatic hydrotho-
rax in 17 out of 163 patients (10.4%). Twenty-one out of 
163 (12.9%) had gastrointestinal bleeding within 4 weeks 
prior to paracentesis.
Forty-eight of 163 patients (29.4%) were on antibiotic 
treatment at the time of paracentesis. In total, 60 of 163 
patients (36.8%) were treated with non-selective beta-
blockers, 82 of 163 patients (50.3%) with proton-pump 
inhibitors and 82 of 163 patients (50.3%) with lactulose at 
the time of paracentesis.
SPB was diagnosed by means of high ascites leukocyte 
counts above 500/mm3 in 21 out of 163 patients (12.9%). 
Infections other than SBP occurred in 38 out of 163 
patients (23.3%), 18 with urinary tract infections, eight 
with pneumonia, five with clostridium difficile-associated 
colitis, three with catheter-associated sepsis, one with 
soft tissue infection, one with pancreatic abscess and two 
with infection of unknown origin.
Sampling of ascites and blood
Paracentesis was performed in all patients at baseline 
(index paracentesis) according to the EASL practice 
guidelines [24] if SBP was suspected or in patients with 
new onset or worsening of ascites. Ascites samples were 
collected under standard aseptic conditions. After skin 
disinfection, local anesthesia was injected. A 14-gauge 
cannula was inserted under ultrasound guidance. The 
first 50 mL of ascitic fluid were discarded to avoid con-
tamination with skin microbiota. The subsequent 50 mL 
fraction was collected and 4  mL of ascitic fluid was 
immediately stored at −80  °C. Whole blood samples 
drawn on the day of paracentesis were available in a sub-
group of 31 patients. Blood was centrifuged at 2500g and 
plasma was stored at −80 °C.
Detection of ascites and plasma microparticles
Samples were isolated by two-step ultracentrifugation, 
as described previously [17]. Shortly, ascites fluid or 
plasma was thawed  and 1  mL was ultracentrifuged at 
10,000g for 30 min at 5 °C. In a second step the superna-
tant was ultracentrifuged by 100,000g for 90 min at 5 °C. 
After ascites fluid or plasma was discarded, plasma MPs 
were resuspended in 300 μL sterile filtered (0.2 µm) PBS, 
ascites MPs were resuspended in 200  µL sterile  filtered 
(0.2  µm)  PBS and all MPs were stored at −80  °C [17]. 
MPs were identified by flow cytometry. Analysis was 
performed on a FACS Canto  II using DiVa software 
(BD Bioscience, San Jose, USA). MPs were identified by 
their characteristic forward and sideward scatter, which 
were set at logarithmic gain. MPs were simulated using 
different sizes of standard microbeads (0.5–1.0 μm, Inv-
itrogen), and a microparticle gate (MP gate) was deter-
mined using these standards. The MP gate included 
1.0  μm beads in its upper and outer corner so that it 
would contain all microparticles 1.0 μm or less. Events in 
the MP gate were further assessed with  FACSFlow (BD 
Bioscience, San Jose, USA) and  filtered (0.2  µm) PBS 
alone to distinguish true events from electronic noise. 
Event numbers of equal sample volumes were counted for 
60 s with a flow rate of 120 µL/min. The measurements of 
all samples were performed on 1 day to avoid day-to-day 
variability of the flow cytometer. Furthermore, each sam-
ple was measured at least twice in random order to fur-
ther minimize measurement variations. The total number 
of microparticles in the samples was calculated by multi-
plying the measured number of events with the ratio of 
total volume to measured volume. Values were reported 
as counts per microliter.
Microparticle labeling and detection
In a subgroup of 60 patients ascites MPs were stained 
with antibodies against surface antigens which allow to 
allocate their origin to either neutrophils (CD66b) or 
lymphocytes (CD3). For that purpose 20, non-survivors 
with low ascites MP levels (<488.4 MP/μL) were matched 
with two survivors, one with low and one with high 
ascites MP level, according to the MELD score and age. 
Respectively, 50  µL MPs were incubated with labeled 
antibodies FITC-CD3 (UCHT1, lymphocytes, Biolegend, 
San Diego, USA), APC-CD66b (G10F5; granulocytes, 
Biolegend, San Diego, USA) for 15 min at RT. 450 µL of 
cold sterile filtered (0.2 µm) FACS buffer (PBS, 1% BSA, 
0.1%  NaN3) and 25  µL counting beads (Biolegend, San 
Diego, USA) were added. Analysis was performed on a 
FACS LSRFortessa using DiVa software (BD Bioscience, 
San Jose, USA) with the same approach and gates as 
described before. Prior measurements unbound antibody 
in FACS buffer as well as isotype controls (APC mouse 
IgM, FITC mouse IgG1; Biolegend, San Diego, USA) 
were run to exclude background and non-specific bind-
ing from real events. The number of positive MP was cal-
culated relative to the number of all gated MPs by FACS 
(Additional file 1: Figure S1).
Statistical analysis
Continuous variables were displayed as mean  ±  stand-
ard deviation or median with range, as appropriate. Cat-
egorical variables have been depicted as frequency and/
or percentage. Mann–Whitney U test was used to com-
pare continuous data and Chi square test for discrete 
data. A two-sided p value lower than 0.05 was considered 
statistically significant. Spearman-Rho correlation coeffi-
cient was used to display potential associations between 
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variables. Survival was evaluated considering all events 
that occurred from the time of inclusion until 30  days 
after inclusion. Follow-up data were collected retrospec-
tively by screening data gathered during clinically indi-
cated visits. Patients or their relatives were contacted if 
follow-up data were not available. Data were censored 
at transplantation or at last patient contact. For survival 
analysis, Kaplan–Meier analysis was performed and the 
log-rank test was used for group comparison. All labora-
tory and clinical data were considered for Cox regression 
analysis to identify potential risk factors for short-term 
death (within 30  days). Factors that were significantly 
associated in univariate analysis were used for multivari-
ate analysis.
Results
Detection of microparticles
MPs were detected in all ascites (n  =  163) and blood 
samples (n = 31) with a median MP count of 281.5 MP/
μL in ascites (range 17.5–32,575.7) and 1469.7 (range 
301.8–4926.3; (p =  0.357) in blood. Absolute MP levels 
in ascites samples correlated to individual MP levels in 
blood (r = 0.444, p = 0.011) (Fig. 1). A considerable num-
ber of patients showed higher MP levels in ascites than 
in blood samples (n = 11, 35.5%) and vice versa (n = 20, 
64.5%), (Additional file 1: Figure S2).
Ascites MP levels correlated weakly with the throm-
bocyte count (r = 0.295, p = 0.0001) and inversely with 
the MELD score (r = −0.198, p = 0.013, Fig. 2a, b), but 
not with age, Child–Pugh score, serum albumin, white 
blood cell counts, AST, GGT, CRP, GFR, ascites pro-
tein content or the ascites leukocyte count. Blood MP 
levels also showed no significant correlation with the 
aforementioned parameters (Table 2). Ascites and blood 
MP levels at index paracentesis were not associated with 
the following baseline parameters: sex, presence of HCC, 
antibiotic treatment and non-selective beta-blocker use 
(Additional file 1: Table S1).
Association between microparticles and patient outcomes
Thirty-one of 163 patients (19%) died and two of 163 
patients (1.2%) were transplanted within 30  days after 
study inclusion. Using the Cox regression analysis, ascites 
MP counts were shown to be significantly associated 
with the 30-day survival. There was an inverse correla-
tion between risk of death and the ascites MP count (per 
100 MP/µL: HR 0.928 (95% CI 0.862–0.999), p = 0.048). 
In patients who died or were transplanted within 30 days 
after paracentesis, ascites MP levels were significantly 
lower [median 180.5 (32.5–2851.6) MP/μL] as compared 
to patients surviving this period [325.1 (17.5–32,575.1) 
MP/μL, p = 0.005], (Fig. 3).
After ROC analysis, the best ascites MP quantifica-
tion cut-off for predicting the 30-day mortality rate was 
488.4 MP/μL with a sensitivity of 90.3% and a specificity 
of 44.7% and an area under the curve (AUROC) of 0.663 
(95% CI 0.564–0.763) (p = 0.005).
Kaplan–Meier analysis showed that patients with 
low levels of MPs in ascites (<488.4 MP/μL, n  =  101) 
had a lower 30-day survival rate of 71.7% when com-
pared to 94.7% in patients with high levels of MP in 
ascites (>488.4 MP/μL, n = 62), (p = 0.0001) (Fig. 4). In 
patients with high ascites MP levels the median biliru-
bin level [28.8 µmol/L (range 5.9–254.2) vs. 44.7 µmol/L 
(range 2.9–609.1, p = 0.04)] were slightly lower and the 
median thrombocyte count higher [141 exp9/L (range 
34–864) vs. 116 exp9/L (range 16–826, p = 0.001)] than 
in patients with low ascites MP levels. All other base-
line parameters were not different between both groups. 
Interestingly, blood MP levels were not associated with 
short-term survival.
Main cause of death was liver failure (Table 3) and sep-
sis. However, nine of 31 patients were lost to follow up 
after discharge from the hospital with regard to the cause 
of death.
Factors associated with patients’ outcome
After univariate analysis, five factors were significantly 
associated with 30-day survival in this study cohort: 
thrombocyte count, MELD score, antibiotic treatment at 
paracentesis, ascites leukocyte count and low ascites MP 
counts (<488.4/μL). After adjustment with these risk fac-
tors by using a multivariate cox regression analysis three 
parameters remained being associated with death: low-
level ascites MPs (<488.4/μL), the MELD score and anti-
biotic treatment at paracentesis (Table 4).
Fig. 1 Correlation of microparticle levels between blood and ascites 
samples. Analysis was performed by Spearman-Rho. The ascites 
microparticles axis is scaled logarithmically
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Antibody labelling of ascites microparticles
Ascites MPs were labelled with antibodies capturing 
surface antigens from either neutrophils (CD66b) or 
lymphocytes (CD3) in a subpopulation of 60 matched 
patients. In general, the median relative amount of 
neutrophil-derived MPs was 32.2% (range 19.3–82.3) 
whereas the median relative amount of lymphocyte-
derived MPs was 12.3% (range 0.6–66.5). There was a 
good correlation (r =  0.865; p  <  0.0001) between both 
MP subsets in ascites and a weak correlation between 
the MELD score and neutrophil-derived MPs (CD66b 
r =  0.313, p =  0.016; CD3 0.158, p =  0.231). Conven-
tional inflammatory parameters such as the CrP level 
and white blood cell count (CrP: CD66b r  =  0.89, 
p  =  0.526, CD3 r  =  0.03, p  =  0.83; WBC: CD66b 
r = −0.035, p = 0.79, CD3 r = −0.106, p = 0.424) and 
the leukocyte count in ascites (CD66b r  =  −0.052, 
p = 0.698; CD3 r = −0.106, p = 0.427) were not asso-
ciated with the relative amount of immune cell-derived 
MP subsets. Patients who died with a low ascites MP 
count (<488.4/μL) had a higher relative amount of both, 
neutrophil and lymphocyte-derived MPs, than patients 
Fig. 2 Correlation between ascites microparticle level and the thrombocyte count (a) as well as the MELD score (b) in blood. a The thrombocyte 
count in blood was weakly correlated with the level of microparticles per microliter ascites. Chart axis is scaled logarithmically. b The MELD score in 
blood was weakly correlated with the level of microparticles per microliter ascites. MELD axis is scaled logarithmically
Table 2 Correlation between clinical baseline parameters and microparticles in ascites and blood
Spearman-Rho correlation (r) was used for analysis
Values highlighted in italics are significant after multivariate analysis
Variable Ascites microparticles (n = 163) Blood microparticles (n = 31)
Correlation coefficient (r) Level of significance (p) Correlation coefficient (r) Level of significance (p)
Age (years) 0.042 0.590 0.144 0.440
Child–Pugh score −0.092 0.390 −0.249 0.263
MELD score −0.198 0.013 −0.318 0.990
Serum albumin (g/L) 0.056 0.584 0.286 0.196
Thrombocyte count (exp9/L) 0.295 0.001 0.140 0.461
WBC count (exp9/L) 0.047 0.570 0.067 0.726
AST (μkat/L) 0.071 0.423 0.011 0.953
GGT (μkat/L) 0.142 0.112 −0.009 0.956
CrP (mg/L) −0.020 0.818 0.227 0.245
GFR (mL/min) 0.072 0.474 −0.040 0.862
Ascites protein content (g/L) 0.001 0.988 0.366 0.060
Ascites leukocyte count (/mm3) 0.050 0.951 0.121 0.516
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who survived or were transplanted [CD66b: median 
43.1% (range 22.7–80) vs. median 29.1% (range 19.3–
82.3), p  =  0.01; CD3: median 18.1% (range 2.7–66.5) 
vs. 7.6% (range 0.6–50.8), p  =  0.044)]. Moreover, the 
relative amount of immune cell-derived MPs of median 
43.1% (range 25.1–81.3) for CD66b and median 22.4% 
(range 2.5–50.8) for CD3 in survivors with low ascites 
MP levels was comparable to non-survivors with low 
ascites MP levels (CD66b p  =  0.578, CD3 p  =  0.963) 
and significantly higher than in survivors with high 
ascites MP levels (CD66b median 25.6% (range 19.3–
65.4), p  =  0.006; CD3 median 3.9% (range 0.6–43.9), 
p = 0.0003) (Fig. 5a–d).
Fig. 3 Total ascites microparticles levels in survivors and in patients 
who died or were transplanted. Although the range was wide, survi-
vors showed significantly higher MP levels
Fig. 4 30-day survival analysis using Kaplan–Meier. Low levels of ascites microparticles were associated with poor short-term survival (30-day)
Table 3 Cause of  death (n =  31) taking into  account the 
quantitative level of microparticles in ascites
Liver failure was the main cause of death
Ascites MP 
level
Cause of death
Liver failure Sepsis Bleeding Cardiac Unknown
<488.4/μL 
(n = 101)
n = 10 n = 6 n = 2 n = 2 n = 8
>488.4/μL 
(n = 62)
n = 1 n = 1 n = 0 n = 0 n = 1
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Table 4 Univariate and multivariate analysis using Cox regression analysis
High MELD score, antibiotic treatment at paracentesis and low-level ascites MP (<488.4 MP/μL) were independent risk factors for death after 30 days
Values highlighted in italics are significant after multivariate analysis
Variable Univariate analysis Multivariate analysis
Hazard  
ratio
95% confidence 
interval
Level of  
significance (p)
Hazard  
ratio
95% confidence 
interval
Level of  
significance (p)
Thrombocyte count 
(exp9/L)
0.992 0.984–0.999 0.024 0.999 0.991–1.007 0.724
MELD score 1.167 1.097–1.241 <0.0001 1.132 1.056–1.214 <0.0001
Antibiotic treatment at 
paracentesis
3.422 1.518–7.718 0.003 2.759 1.095–6.952 0.031
Ascites leukocyte count 
(exp9/L)/100
1.019 1.001–1.037 0.039 0.997 0.958–1.038 0.900
Low-level ascites MPs 
(<488.4/μL)
6.552 1.991–21.561 0.002 8.723 1.148–66.308 0.036
Fig. 5 Relative amount of neutrophil (CD66b) and lymphocyte (CD3)-derived ascites microparticles compared between non-survivors and survi-
vors (a, c) and according to the ascites MP levels (b, d). Non-survivors had a higher rate of CD66b positive (a) and CD3 positive (c) microparticles. b 
Patients with low ascites microparticle levels (<488.4/μL) had a higher relative amount of CD66b positive (b) and CD3 positive (d) ascites microparti-
cles compared to patients with high ascites microparticle levels irrespective of their survival status. *p < 0.05; **p < 0.01; ***p < 0.001
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Discussion
Plasma MPs, in particular cell specific subtypes, have 
been investigated as novel biomarkers for several patho-
mechanistic processes. We wanted to determine whether 
MPs are released into cirrhotic ascites in the first place 
and, if so, whether overall quantification levels correlate 
with clinical endpoints in cirrhosis.
This is the first report about ascites MPs in patients 
with liver cirrhosis. Our study indicates that MPs are 
ubiquitously present in cirrhotic ascites. This is in line 
with previous investigations that focused on MP diag-
nostics in ascites of patients with peritonitis and ovar-
ian neoplasms. Those studies have shown that MPs can 
be found in peritoneal fluid irrespective of the diagnostic 
method used (electron microscopy or flow cytometry) 
and of the cause of ascites [20, 21].
Our survival analysis emphasized the clinical relevance 
of absolute ascites MP levels in cirrhosis. Patients with 
a cut-off level below 488.4 MP/μL died more frequently 
than patients with high levels (30-day survival: <488.4 
MP/μL 71.1% vs. >488.4 MP/μL 94.7%, HR 8.571) along 
with the liver function and other clinical or laboratory 
parameters at baseline. The high rate of liver failure caus-
ing death indicated to some extent that patients with low 
ascites MP levels are in the final stages of cirrhosis. It is 
important to highlight that we observed an inverse corre-
lation between ascites MP levels and patients’ prognosis 
whereas in the literature cell-specific plasma MP levels 
rise with disease progression. This might be explained 
by a formation of MP-associated immune complexes 
[25], which is a phenomenon observed in synovial fluid 
of patients with rheumatoid arthritis by using electron 
microscopy and a new generation of flow cytometers. 
Generally, those formations are highly active and pro-
inflammatory and probably express an inflammatory sys-
temic reaction [25]. These complexes would have been 
missed with the conventional flow cytometers that we 
used as particle size significantly increases (>1 µm) after 
complex formation. We gated only particles with a diam-
eter smaller than 1  µm, so that we cannot exclude the 
presence of high volume complexes.
This theory is supported by the fact that the rate of 
MPs derived from neutrophils and lymphocytes are 
much higher in patients with low ascites MP levels and 
associated with the severity of liver dysfunction, dis-
played by the MELD score. This observation is well in 
line with the notion that end stage cirrhosis is accom-
panied by an inflammatory state [26, 27]. Nevertheless, 
further prospective studies are needed to substantially 
clarify the missing correlation with conventional inflam-
matory parameters as well as the underlying relationship 
between ascites MPs and patient outcomes. We sug-
gest screening for MP complexes using new generation 
cytometers on the one hand and screening for further 
surface antigens in order to identify more cell types, 
which release MPs in ascites on the other hand. Subse-
quently performed ex vivo cell-specific stimulation tests 
to produce MPs can clarify if cell exhaustion is an actual 
problem in the peritoneal cavity.
Interestingly, the amount of MP production in ascites 
but also in blood from patients with cirrhosis seems to 
be highly variable, with MP levels in ascites ranging 
from 17.5 to 32,575.7 MP/µL, and in blood from 301.8 to 
4926.3  MP/µL. This gives rise to at least two questions. 
The first is which host factors apart from inflammatory 
processes influence the release of MPs. The second is 
whether ascites MPs are derived from circulating blood 
cells or directly produced by autochthonous peritoneal 
cells. The latter might explain why we not only had a 
weak correlation between plasma and ascites MP levels 
but also a considerable number of patients with ascites 
MP levels higher than those in plasma. In this context 
it is important to emphasize that blood sample size was 
rather low potentially reducing its informative value. 
Nevertheless, the fact that there were no true correla-
tions of overall MP levels, both in ascites and blood, with 
clinical parameters and immune cell MPs were upregu-
lated in patients with high risk of death suggests that it 
is worthwhile again to focus on MP subsets in order to 
clarify the cause of overall ascites MP loss in high risk 
patients and the high variability. Notably, it is known that 
specific types of circulating MPs are involved in patho-
genic processes such as endothelial dysfunction [4, 11, 
23, 28, 29], coagulatory processes [9, 30] and inflamma-
tory reactions [7, 31–33]. In recent years, there has been 
growing evidence that plasma MPs reflect disease sever-
ity in chronic liver diseases. Korneck et  al. [16] investi-
gated 67 patients with fatty liver disease and 42 patients 
with chronic hepatitis C and compared them to healthy 
individuals in terms of immune cell-derived plasma MP 
levels. We evaluated stem cell-derived plasma MP lev-
els in acute as well as acute-on-chronic liver failure in 
rodents and humans (n = 10) [17]. Both studies showed 
that relative levels of immune cell- and stem cell-derived 
MPs were increased with heightened disease activity 
measured by transaminases and liver function tests in 
individuals with liver insufficiency. To what extend those 
results and others [34–38] related to circulating MPs can 
be extrapolated to ascites MPs is speculative at this stage, 
so that re-examinations are mandatory.
Our study has certain limitations. Due to the retro-
spective evaluation of all clinical data, some values were 
missing. Specific information concerning cause of death 
was not available for 9 of 31 patients who died during the 
observational period. Although the PMN count in ascitic 
fluid is the diagnostic gold standard for SBP, we used the 
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ascites leukocyte count, because the ascites cell count 
could not be differentiated during the sample collection 
period. This might be a source of inaccuracy in terms of 
the relevance of infectious complications. However, the 
total leukocyte count has also been evaluated as a reliable 
diagnostic mean for SBP [22]. Moreover, ascites samples 
have not been centrifuged before freezing. Variation in 
temperature make cells (erythrocytes and leukocytes) 
explode and release membranes resembling MPs. How-
ever, cells and fragments of cells were removed by the 
first centrifugation step. If remaining cells had an influ-
ence on MP levels in our setting, we should have found 
a high correlation of the ascites leucocyte count with 
the MP levels, which is not the case. It is unclear as to 
whether MP levels correlated with the amount of ascites 
as a high ascites volume might be associated with low MP 
concentrations and vice versa. However, this parameters 
has not been documented. The fact that we were able 
to detect surface antigens from the original cell empha-
sizes that true MPs and not debris was captured by flow 
cytometry in ascitic fluid.
Conclusions
In summary, absolute ascites MP levels represent a novel 
independent prognostic factor in patients with decom-
pensated liver cirrhosis. Note that the detection of abso-
lute MP levels from ascites samples was shown to be easy, 
reliable and cost-effective, which is important in the con-
text of potential clinical implementation. Before MPs can 
be evaluated as biomarkers in cirrhosis, it is essential to 
clarify the mechanisms behind the association between 
overall ascites MP levels and clinical endpoints observed 
in this study. High levels of neutrophils and lymphocyte 
surface antigens in patients with low level ascites MPs 
suggests that immune reactions are involved in the path-
omechanisms explaining the high risk of death in those 
patients.
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